| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SLGL Stock Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
Sol-Gel Technologies Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.49 |
| 52 Week High | US$16.69 |
| 52 Week Low | US$6.12 |
| Beta | 1.21 |
| 1 Month Change | 4.17% |
| 3 Month Change | -19.89% |
| 1 Year Change | -28.26% |
| 3 Year Change | 28.92% |
| 5 Year Change | n/a |
| Change since IPO | -45.09% |
Recent News & Updates
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| SLGL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.8% | -3.5% | -3.5% |
| 1Y | -28.3% | 7.1% | 10.2% |
Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: SLGL underperformed the US Market which returned 13.7% over the past year.
Price Volatility
| SLGL volatility | |
|---|---|
| SLGL Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: SLGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SLGL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 65 | Alon Seri-Levy | https://www.sol-gel.com |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Fundamentals Summary
| SLGL fundamental statistics | |
|---|---|
| Market Cap | US$173.16m |
| Earnings (TTM) | -US$17.30m |
| Revenue (TTM) | US$12.52m |
13.8x
P/S Ratio-10.0x
P/E RatioIs SLGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGL income statement (TTM) | |
|---|---|
| Revenue | US$12.52m |
| Cost of Revenue | US$21.05m |
| Gross Profit | -US$8.53m |
| Expenses | US$8.77m |
| Earnings | -US$17.30m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | -68.13% |
| Net Profit Margin | -138.14% |
| Debt/Equity Ratio | 0% |
How did SLGL perform over the long term?
See historical performance and comparisonValuation
Is Sol-Gel Technologies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SLGL ($7.49) is trading below our estimate of fair value ($25.84)
Significantly Below Fair Value: SLGL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SLGL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: SLGL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLGL is overvalued based on its PB Ratio (4.2x) compared to the US Pharmaceuticals industry average (2.3x).
Future Growth
How is Sol-Gel Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
54.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLGL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLGL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLGL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLGL's revenue (20.3% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: SLGL's revenue (20.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLGL's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Sol-Gel Technologies performed over the past 5 years?
0.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLGL is currently unprofitable.
Growing Profit Margin: SLGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLGL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare SLGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLGL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: SLGL has a negative Return on Equity (-41.74%), as it is currently unprofitable.
Financial Health
How is Sol-Gel Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: SLGL's short term assets ($48.1M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: SLGL's short term assets ($48.1M) exceed its long term liabilities ($1.9M).
Debt to Equity History and Analysis
Debt Level: SLGL is debt free.
Reducing Debt: SLGL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLGL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SLGL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Sol-Gel Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SLGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLGL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SLGL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.4yrs
Average management tenure
CEO
Alon Seri-Levy (60 yo)
25yrs
Tenure
US$636,000
Compensation
Dr. Alon Seri-Levy is a Co-Founder at Sol-Gel Technologies Ltd. in 1997 and has been its Chief Executive Officer since 1997. Dr. Seri-Levy established the computer-aided drug design department at Peptor Lt...
CEO Compensation Analysis
Compensation vs Market: Alon's total compensation ($USD636.00K) is below average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Alon's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: SLGL's management team is seasoned and experienced (5.4 years average tenure).
Board Members
Experienced Board: SLGL's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sol-Gel Technologies Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Sol-Gel Technologies Ltd.
- Ticker: SLGL
- Exchange: NasdaqGM
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$173.162m
- Shares outstanding: 23.12m
- Website: https://www.sol-gel.com
Number of Employees
Location
- Sol-Gel Technologies Ltd.
- 7 Golda Meir Street
- Weizmann Science Park
- Ness Ziona
- 7403650
- Israel
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/18 23:55 |
| End of Day Share Price | 2022/01/18 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.